Gilead: Truvada Will Pass FDA Approval
By Qineqt:Last Friday, the Food and Drug Administration (FDA) delayed the approval of two HIV-drugs, Truvada and Quad, until September. However, Truvada has already been a treatment drug and is prescribed by some doctors as a preventive measure as well. Only one out of the fourteen members of the FDA panel has raised concerns about Quad, a new once-a-day, one-pill combination of four drugs. Despite this delay, we believe that both these drugs are going to be approved and will help Gilead Sciences (GILD) to improve its competitive position in the HIV drugs' market.
Investment thesis:
Gilead is the leading company in HIV market. Its pills (Atripla and Truvada) are the market leaders for HIV treatment. After FDA approval, Truvada will also be used as a prevention drug along with its current use as a treatment drug. The FDA panel has also endorsed Gilead's new pill, Quad, that is the simplestComplete Story »
- Original article
- Login or register to post comments
